Tel Hashomer Medical Research Infrastructure and Services Ltd.

Yeda Research and Develpment & Co. Ltd

Tel Aviv University

Tageza Biopharmaceuticals Ltd.

Benjamin Dekel

Orit Harari-Steinberg

Yair Reisner

Anna Aronovich

Elias Shezen

Smadar Eventov-Friedman

Dalit Tchorsh

Helena Katchman

Einav Vax

Naomi Pode-Shakked

Dalit Tchorsh-Yutsis

Orit Harai-Steinberg

Ella Buzhor

Michal Mark-Danieli

Sanja Goldberg

Methods of treating cancer are provided. Accordingly, there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent capable of (i) specifically binding GABRA2, the agent comprising a therapeutic moiety; and/or (ii) downregulating activity and/or expression of said GABRA2. Also provided are compositions, article of manufactures and methods of diagnosing cancer and monitoring cancer treatment.

Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

A method of identifying cancer stem cell markers in a human primary tumor is disclosed. The method comprises:

Identification of cancer stem cells markers and use of same for diagnosis and treatment

A method of generating a nephrospheroid is disclosed. The method comprises culturing human adult kidney cells in a culture medium under non-adherent conditions. Uses thereof and other renal cell populations are also disclosed.

Isolated populations of adult renal cells and methods of isolating and using same

The invention provides antibodies or an antigen-binding portion thereof, which recognize the human Frizzled 7 receptor. Further, the invention provides methods of using these antibodies for the treatment cancer in a subject.

Frizzled receptor antibodies for treatment of cancer

Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.

Isolated populations of renal stem cells and methods of isolating and using same

A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor phenotype. Cell populations generated thereby and uses thereof are also disclosed.

Methods of reprogramming renal cells

A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject.

Disease treatment via developing non-syngeneic graft transplantation

A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.

Growing community of inventors

Tel Aviv, Israel

Benjamin Dekel